Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on July 16, 2021. The report details compensatory arrangements approved by the Compensation Committee for executive officers and independent directors, effective June 1, 2021.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change reported is the increase in base salaries and the granting of cash bonuses and stock options to key personnel:
- Executive Officers: James Martin (CFO/Co-Interim CEO) and Sam Lee (President/Co-Interim CEO) received base salary increases from $315,000 to $350,000 annually.
- Cash Bonuses: Each executive officer received a one-time cash bonus of $100,000.
- Stock Options (Executives): Each executive received 250,000 incentive stock options.
- Stock Options (Directors): Independent directors received grants ranging from 50,000 to 88,000 non-qualified stock options.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies. The stock options granted to both executives and directors are exercisable at $1.11 per share with a ten-year term. Vesting schedules require continuous employment or service, with 50% vesting on the one-year anniversary and the remainder in quarterly installments starting September 30, 2022.
Key Facts for Investor Verification
- Verify the total dilution impact of the 500,000 options granted to executives and approximately 342,000 options granted to directors.
- Confirm the company's cash position to ensure it can fund the $200,000 in immediate cash bonuses to executives.
- Review the vesting conditions to understand the retention timeline for leadership and board members.
- Check the current trading price of COCP relative to the $1.11 exercise price to assess the intrinsic value of the grants.